
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics has demonstrated consistent growth in EsoGuard test volumes, with a year-over-year increase to 2,841 tests in Q3 2025, suggesting a solid demand for their diagnostic solutions. The company is poised for rapid revenue growth as it expands insurance coverage, particularly anticipating positive impacts from Medicare coverage and other payer sources in the second half of 2025. Additionally, a favorable Medicare coverage decision follows a successful MolDX CAC meeting, indicating potential for increased patient access and market expansion, thus enhancing Lucid Diagnostics' financial prospects.
Bears say
Lucid Diagnostics Inc. reported revenues in 3Q25 that fell short of consensus expectations, indicating challenges in customer adoption and market penetration of its EsoGuard product. The company recorded a pro forma net loss of $10.3 million, slightly worse than anticipated, alongside ongoing balance sheet and liquidity risks that could hinder future growth. Additionally, a decline in the number of EsoGuard tests processed, coupled with potential reimbursement issues and increasing competition, heightens uncertainties surrounding its operational and financial viability.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares